Full-Body Pressure Sensing
A high-resolution flexible sensor array generates real-time pressure maps across the entire body, detecting position, posture, movement phase, and fall risk — with 96.5% average accuracy in ML-based position recognition.
NIH SBIR FundedBrigham & Women's HospitalPCT Patent Filed
40 million Americans need repositioning in bed.No solution exists. We're building it.
Soterya is building Korus — the first AI-robotic platform for autonomous patient repositioning. Born from life-saving epilepsy research at Harvard, now targeting a $548M annual revenue opportunity across six markets — with no direct competitors. $3.7M NIH-funded. Consumer launch 2026.
Korus — Prone to Recovery PositionRepositioning in <30 seconds · 96.5% position accuracy
◆ $3.7M non-dilutive funding secured◆ Founded 2020, Boston MA◆ Published peer-reviewed research
01 — Why This Exists
Born from a life-or-death problem.
Scaled to help millions.
In epilepsy, sleeping face down after a seizure increases the risk of sudden death (SUDEP) by up to 85%. Patients need to be repositioned within minutes — but caregivers aren't always there.
That's why neurologist Dr. Jong Woo Lee at Brigham and Women's Hospital and product engineer Andres Rodriguez co-founded Soterya in 2020 — to build a mattress that could reposition patients autonomously. They were joined by scientist-entrepreneur Dr. Lina Williamson and communications director Valentina Mendez.
What they built — Korus — turned out to solve a much bigger problem: 40 million+ Americans need daily repositioning in bed, from elderly adults aging at home to patients recovering from surgery. The same AI-robotic platform that could save epilepsy patients' lives can prevent pressure injuries, relieve chronic back pain, manage snoring, and reduce the devastating physical toll on caregivers.
40M+
People in the U.S.
require daily or scheduled repositioning to prevent complications or assist with in-bed mobility — from seniors aging in place to nursing home residents to post-surgical patients.
Media — Why This ExistsUpload image or video
02 — The Technology
A smart robotic surface that
monitors, learns, and moves
Korus combines an array of expandable smart cells, high-resolution pressure sensing, on-device machine learning, and a proprietary simulation system (BES) — all working in a closed loop to reposition patients autonomously.
On-Device AI
Edge computing runs adaptive ML models that learn user-specific patterns and generate personalized repositioning strategies. A proprietary Bed Environment Simulation (BES) system creates virtual training data to accelerate learning.
Expandable Smart Cells
Patented pneumatic cells expand up to 15 inches, each with integrated sensors for motion, pressure, temperature, sound, and humidity. The array deforms dynamically to reposition users in under 30 seconds.
Any Position, Any Body Type
Korus operates in every sleeping position — side, back, or prone — and adapts to any body type and weight. Its flexible, multidirectional cell architecture conforms to each individual, delivering personalized support without compromise.
Manual & Autonomous via App
Korus facilitates both manual and autonomous repositioning through a friendly companion app for iOS and Android. Caregivers and users can trigger repositioning, set schedules, adjust firmness zones, and review sleep insights — all from their phone.
No Wearables, No Disruption
Korus monitors your sleep and position without requiring you to wear any device. No bands, no patches, no changes to your sleep rituals. All sensing happens through the surface itself — invisible, contactless, and always on.
Media — Technology DemoUpload image or video
03 — Market Opportunity
One platform, six markets,
$548M+ annual revenue potential
Korus enters as a consumer wellness product — then scales to medical-grade applications through FDA clearance. The same hardware powers every use case; software unlocks each market.
$10.5B
Aging in Place
Primary go-to-market: 31M+ seniors with mobility impairment. B2B through long-term care facilities and B2C for home use. 70% of seniors 65+ will eventually need long-term care.
$25B
Snoring + Back Pain
Over 33 million Americans experience chronic snoring or back pain impacted by sleep positioning. Strong B2C adoption with tech-savvy, high-income consumers.
$7B
Medical Applications
Epilepsy (SUDEP prevention), pressure injury prevention, spinal cord injury, and ICU care. No direct competitors. FDA De Novo pathway planned with Breakthrough Device designation.
Media — Market OpportunityUpload image or video
04 — Traction & Validation
Backed by the best in science and healthcare
Soterya has progressed from concept to a fully functional prototype with peer-reviewed research, NIH funding, and clinical partnerships at one of the world's top hospitals.
$3.7M
Non-Dilutive Funding
96.5%
Position Accuracy
<30s
Repositioning Time
1
PCT Patent Filed
2
NIH SBIR Grants
$125K
Epilepsy Fdn. Award
Media — Traction & MilestonesUpload image or video
05 — Commercialization Roadmap
Consumer first, medical-grade next
Start with a consumer wellness product to generate early revenue and real-world data. Use that foundation to pursue FDA clearance for life-saving medical applications.
2026 — Consumer Launch
Sleep Wellness & Mobility Support
Korus enters as a DME consumer product for aging in place, snoring relief, back pain management, and general mobility support. Entry price ~$16K, with a target price of $8K–$15K at scale. Direct-to-consumer online sales with demonstration sites in key states.
2026–2028 — Software Expansion
Modular Software Add-Ons
Same hardware, new applications. Autonomous repositioning, scheduled repositioning, bed-exit alerts, fall prevention, and personalized sleep coaching — all delivered via Soterya's app store to unlock recurring revenue.
2029+ — Medical Device
FDA De Novo for Epilepsy & Beyond
Seeking Breakthrough Device designation for SUDEP prevention — repositioning patients from prone to recovery position during seizures. Then expand to pressure injury prevention, spinal cord injury, and ICU applications via 510(k).
Consolidation — Reimbursement
DME + NTAP Pathways
Pursue insurance reimbursement through Durable Medical Equipment (DME) for home use and New Technology Add-On Payment (NTAP) for inpatient hospital settings. Working with regulatory consultants Accorto and Kalms Consulting.
Media — Commercialization RoadmapUpload image or video
06 — Competitive Advantage
What makes Korus different from
everything else on the market
Traditional adjustable beds move in one axis. Hospital beds strap patients down. Smart beds like Sleep Number monitor but never intervene. Korus is the only platform that combines AI-driven monitoring with autonomous full-body repositioning.
Monitoring + Intervention
Competitors monitor sleep or adjust firmness. Korus is the first to autonomously reposition specific body parts to any orientation — not just raise the head or feet.
Non-Restrictive Design
Unlike hospital rotation beds, patients aren't strapped down. Korus' smart-rail design uses dynamic surface deformation — one section moves the patient, another prevents rolling off, a third supports the head.
Platform + Software Model
One hardware platform, unlimited software applications. Each medical indication (epilepsy, pressure injuries, sleep apnea) is a software add-on — creating recurring revenue and expanding TAM without new hardware.
Media — Competitive AdvantageUpload image or video
07 — The Founders
Neurology × Engineering × Science × Operations
JL
Dr. Jong Woo Lee
Co-Founder & Medical Director
Associate Professor of Neurology, Division of Epilepsy at Brigham and Women's Hospital / Harvard Medical School. Extensive clinical expertise in epilepsy and SUDEP.
AR
Andres Rodriguez
Co-Founder, CCO & CPO
9+ years in biotech/medical devices, 10+ in marketing and product development. Previously consulted for Colgate, PepsiCo, J&J. Expertise in biomedical engineering, electronics, and simulation.
LW
Dr. Lina Williamson
Co-Founder & CEO
DVM, PhD. Scientist entrepreneur with extensive bio-pharmaceutical industry experience. MIT Fellow. Bridges academic research and commercial viability in healthcare.
VM
Valentina Mendez
Co-Founder, Dir. Operations
Communications and public relations leader. Manages operations, community engagement, and partnerships with advocacy groups including the Epilepsy Foundation and Danny Did Foundation.
08 — Investor Perks
Own a piece of the future of sleep
Every investor receives equity in Soterya, Inc. Higher tiers unlock exclusive pricing and early access to Korus.
Visionary Investor
$100+
- Equity stake in Soterya, Inc.
- Quarterly investor updates
- Founding investor community access
- Name on Soterya's Founding Wall
Pioneer Investor
$1,000+
- Everything in Visionary
- Priority access to first Korus production run
- Exclusive investor discount on Korus
- Early access to the Korus companion app
Frontier Investor
$5,000+
- Everything in Pioneer
- VIP beta testing program
- Annual call with founding team
- Input on future Korus features
World-Shaper Investor
$10,000+
- Everything in Frontier
- Private dinner with founding team
- Advisory input on product roadmap
- Featured investor spotlight on campaign
09 — FAQ
Common questions
What is Korus, exactly?
Korus is an AI-driven smart mattress built on a modular architecture of expandable pneumatic cells. It monitors your body position in real-time using embedded sensors and machine learning, then autonomously repositions you throughout the night — gently enough that you don't wake up. It's controlled via a companion app for iOS and Android.
How is this different from an adjustable bed?
Adjustable beds raise or lower sections in one axis — typically head and feet. Korus can reposition specific body parts in any direction using individually controlled cells across the entire surface. It's not just adjustable — it's autonomous and intelligent, learning your body and needs over time.
What stage is the product in?
Soterya has completed a fully functional MVP with manual repositioning under 30 seconds, 96.5% average ML position recognition accuracy, and a companion app for iOS and Android. Autonomous repositioning features are currently in validation. Pilot studies in nursing homes and assisted living facilities are planned for 2026.
What's the expected price?
The consumer entry price is estimated at ~$16K, competitive with premium smart beds from Sleep Number ($10K+), Tempur-Pedic ($12K+), and Purple ($16K+). The long-term target is $8K–$15K depending on features and size. Investors at higher tiers will receive exclusive discounts.
What is SUDEP and why does it matter?
SUDEP (Sudden Unexpected Death in Epilepsy) is the leading cause of death in young epilepsy patients. Sleeping face down after a seizure increases risk by up to 85%. Korus was originally designed to reposition these patients to a recovery position within seconds — a capability no other product offers. This medical origin story is what makes Korus fundamentally different from any "smart mattress" on the market.
What are the risks of this investment?
As with any early-stage hardware and medical technology company, risks include manufacturing delays, supply chain challenges, regulatory timelines, and market adoption. Soterya mitigates these through its $3.7M in non-dilutive funding, Harvard-affiliated clinical partnerships, phased commercialization strategy (consumer first, medical second), and produce-to-order manufacturing model. Please read the full offering documents before investing.
Invest in the platform that
redefines how we sleep
Soterya is building the first autonomous repositioning system — from life-saving epilepsy care to a $40B+ elderly wellness market. Join the investors backing this mission.